Job Harenberg1, Ingrid Jörg, Christel Weiss. 1. IV. Department of Medicine, University Hospital Mannheim, Theodor-Kutzer-Ufer, 68167 Mannheim, Germany, J-Harenberg@t-online.de
Abstract
OBJECTIVE:Recurrent thromboembolic events may occur after termination of anticoagulant therapy for acute venous thromboembolism (VTE) using oral direct thrombin inhibitor ximelagatran. METHODS:Patients with VTE recruited at the German study centres were followed-up for an additional 18 months, treated initially with 2x36 mg ximelagatran daily or with enoxaparin/warfarin over 6 months (THRIVE Treatment study) and 2x24 mg ximelagatran daily or placebo over 18 months (THRIVE III study). Recurrent VTE and the combined outcome events consisting of recurrent VTE, other thrombotic complication, major bleeding and mortality were analysed. RESULTS: In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding. During follow-up, 4/32 and 3/32 patients initially randomised to ximelagatran and enoxaparin/warfarin developed recurrent VTE (p=0.7024). No major bleed occurred. One patient in each group died. The incidences of the combined outcome events were not different (p=0.9326). In the THRIVE III study, 0/9 versus 5/14 patients randomised to ximelagatran and placebo developed recurrent VTE including 1 fatal pulmonary embolism (p=0.0501). During follow-up, 3/9 and no patients initially randomised to ximelagatran and placebo developed recurrent VTE. One and 3 other outcome events occurred in patients initially randomised to ximelagatran or placebo. During follow-up, recurrent VTE (p=0.6893) and combined outcome events (p=0.3642) were not different between the groups. CONCLUSION: The results of the follow-up studies suggest that thromboembolic events may re-occur in patients with acute VTE after termination of treatment with both vitamin K-antagonists and ximelagatran.
RCT Entities:
OBJECTIVE: Recurrent thromboembolic events may occur after termination of anticoagulant therapy for acute venous thromboembolism (VTE) using oral direct thrombin inhibitor ximelagatran. METHODS:Patients with VTE recruited at the German study centres were followed-up for an additional 18 months, treated initially with 2x36 mg ximelagatran daily or with enoxaparin/warfarin over 6 months (THRIVE Treatment study) and 2x24 mg ximelagatran daily or placebo over 18 months (THRIVE III study). Recurrent VTE and the combined outcome events consisting of recurrent VTE, other thrombotic complication, major bleeding and mortality were analysed. RESULTS: In the THRIVE Treatment study, no patient suffered from a recurrent VTE, but 1 patient randomised to enoxaparin/warfarin experienced major bleeding. During follow-up, 4/32 and 3/32 patients initially randomised to ximelagatran and enoxaparin/warfarin developed recurrent VTE (p=0.7024). No major bleed occurred. One patient in each group died. The incidences of the combined outcome events were not different (p=0.9326). In the THRIVE III study, 0/9 versus 5/14 patients randomised to ximelagatran and placebo developed recurrent VTE including 1 fatal pulmonary embolism (p=0.0501). During follow-up, 3/9 and no patients initially randomised to ximelagatran and placebo developed recurrent VTE. One and 3 other outcome events occurred in patients initially randomised to ximelagatran or placebo. During follow-up, recurrent VTE (p=0.6893) and combined outcome events (p=0.3642) were not different between the groups. CONCLUSION: The results of the follow-up studies suggest that thromboembolic events may re-occur in patients with acute VTE after termination of treatment with both vitamin K-antagonists and ximelagatran.
Authors: S Schulman; A S Rhedin; P Lindmarker; A Carlsson; G Lärfars; P Nicol; E Loogna; E Svensson; B Ljungberg; H Walter Journal: N Engl J Med Date: 1995-06-22 Impact factor: 91.245
Authors: Jean-Noel Fiessinger; Menno V Huisman; Bruce L Davidson; Henri Bounameaux; Charles W Francis; Henry Eriksson; Torbjörn Lundström; Scott D Berkowitz; Per Nyström; Mona Thorsén; Jeffrey S Ginsberg Journal: JAMA Date: 2005-02-09 Impact factor: 56.272
Authors: Paul M Ridker; Samuel Z Goldhaber; Ellie Danielson; Yves Rosenberg; Charles S Eby; Steven R Deitcher; Mary Cushman; Stephan Moll; Craig M Kessler; C Gregory Elliott; Rolf Paulson; Turnly Wong; Kenneth A Bauer; Bruce A Schwartz; Joseph P Miletich; Henri Bounameaux; Robert J Glynn Journal: N Engl J Med Date: 2003-02-24 Impact factor: 91.245
Authors: Bengt I Eriksson; Giancarlo Agnelli; Alexander T Cohen; Ola E Dahl; Patrick Mouret; Nadia Rosencher; Christina Eskilson; Ingela Nylander; Lars Frison; Mats Ogren Journal: Thromb Haemost Date: 2003-02 Impact factor: 5.249
Authors: P Prandoni; A W Lensing; A Cogo; S Cuppini; S Villalta; M Carta; A M Cattelan; P Polistena; E Bernardi; M H Prins Journal: Ann Intern Med Date: 1996-07-01 Impact factor: 25.391
Authors: Clive Kearon; Jeffrey S Ginsberg; Michael J Kovacs; David R Anderson; Philip Wells; Jim A Julian; Betsy MacKinnon; Jeffrey I Weitz; Mark A Crowther; Sean Dolan; Alexander G Turpie; William Geerts; Susan Solymoss; Paul van Nguyen; Christine Demers; Susan R Kahn; Jeannine Kassis; Marc Rodger; Julie Hambleton; Michael Gent Journal: N Engl J Med Date: 2003-08-14 Impact factor: 91.245
Authors: P Klement; S Carlsson; J Rak; P Liao; M Vlasin; A Stafford; M Johnston; J I Weitz Journal: J Thromb Haemost Date: 2003-03 Impact factor: 5.824
Authors: Sam Schulman; Karin Wåhlander; Torbjörn Lundström; Solveig Billing Clason; Henry Eriksson Journal: N Engl J Med Date: 2003-10-30 Impact factor: 91.245